TY - JOUR AU - Siegel, R. L. AU - Miller, K. D. AU - Jemal, A. PY - 2020 DA - 2020// TI - Cancer statistics, 2020 JO - Cancer J Clin. VL - 70 UR - https://doi.org/10.3322/caac.21590 DO - 10.3322/caac.21590 ID - Siegel2020 ER - TY - JOUR AU - Adderley, H. AU - Blackhall, F. H. AU - Lindsay, C. R. PY - 2019 DA - 2019// TI - KRAS-mutant non-small cell lung cancer: converging small molecules and immune checkpoint inhibition JO - EBioMedicine. VL - 41 UR - https://doi.org/10.1016/j.ebiom.2019.02.049 DO - 10.1016/j.ebiom.2019.02.049 ID - Adderley2019 ER - TY - JOUR AU - Tomasini, P. AU - Walia, P. AU - Labbe, C. AU - Jao, K. AU - Leighl, N. B. PY - 2016 DA - 2016// TI - Targeting the KRAS pathway in non-small cell lung cancer JO - Oncologist VL - 21 UR - https://doi.org/10.1634/theoncologist.2015-0084 DO - 10.1634/theoncologist.2015-0084 ID - Tomasini2016 ER - TY - JOUR AU - Ferrer, I. AU - Zugazagoitia, J. AU - Herbertz, S. AU - John, W. AU - Paz-Ares, L. AU - Schmid-Bindert, G. PY - 2018 DA - 2018// TI - KRAS-Mutant non-small cell lung cancer: from biology to therapy JO - Lung cancer. VL - 124 UR - https://doi.org/10.1016/j.lungcan.2018.07.013 DO - 10.1016/j.lungcan.2018.07.013 ID - Ferrer2018 ER - TY - JOUR PY - 2013 DA - 2013// TI - A genomics-based classification of human lung tumors JO - Sci Transl Med. VL - 5 ID - ref5 ER - TY - JOUR PY - 2012 DA - 2012// TI - Comprehensive genomic characterization of squamous cell lung cancers JO - Nature VL - 489 UR - https://doi.org/10.1038/nature11404 DO - 10.1038/nature11404 ID - ref6 ER - TY - BOOK AU - Lindsay, C. R. AU - Jamal-Hanjani, M. AU - Forster, M. PY - 2018 DA - 2018// TI - Blackhall F PB - Reasons for optimism in lung cancer. European journal of cancer CY - KRAS ID - Lindsay2018 ER - TY - JOUR AU - Yoshizawa, A. AU - Sumiyoshi, S. AU - Sonobe, M. AU - Kobayashi, M. AU - Fujimoto, M. AU - Kawakami, F. PY - 2013 DA - 2013// TI - Validation of the IASLC/ATS/ERS lung adenocarcinoma classification for prognosis and association with EGFR and KRAS gene mutations: analysis of 440 Japanese patients JO - J Thorac Oncol. VL - 8 UR - https://doi.org/10.1097/JTO.0b013e3182769aa8 DO - 10.1097/JTO.0b013e3182769aa8 ID - Yoshizawa2013 ER - TY - JOUR AU - ElOsta, B. AU - Behera, M. AU - Kim, S. AU - Berry, L. D. AU - Sica, G. AU - Pillai, R. N. PY - 2019 DA - 2019// TI - Characteristics and outcomes of patients with metastatic KRAS-mutant lung adenocarcinomas: the lung cancer mutation consortium experience JO - J Thorac Oncol. VL - 14 UR - https://doi.org/10.1016/j.jtho.2019.01.020 DO - 10.1016/j.jtho.2019.01.020 ID - ElOsta2019 ER - TY - JOUR AU - Janne, P. A. AU - Yang, J. C. AU - Kim, D. W. AU - Planchard, D. AU - Ohe, Y. AU - Ramalingam, S. S. PY - 2015 DA - 2015// TI - AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer JO - N Engl J Med. VL - 372 UR - https://doi.org/10.1056/NEJMoa1411817 DO - 10.1056/NEJMoa1411817 ID - Janne2015 ER - TY - JOUR AU - Thai, A. A. AU - Solomon, B. J. PY - 2018 DA - 2018// TI - Treatment of ALK-positive nonsmall cell lung cancer: recent advances JO - Curr Opin Oncol VL - 30 UR - https://doi.org/10.1097/CCO.0000000000000431 DO - 10.1097/CCO.0000000000000431 ID - Thai2018 ER - TY - JOUR AU - Loh, Z. AU - Mitchell, P. AU - John, T. AU - Arulananda, S. PY - 2019 DA - 2019// TI - RET-rearranged non-small-cell lung cancer and therapeutic implications JO - Intern Med J. VL - 49 UR - https://doi.org/10.1111/imj.14654 DO - 10.1111/imj.14654 ID - Loh2019 ER - TY - JOUR AU - Scheffzek, K. AU - Ahmadian, M. R. AU - Kabsch, W. AU - Wiesmuller, L. AU - Lautwein, A. AU - Schmitz, F. PY - 1997 DA - 1997// TI - The Ras-RasGAP complex: structural basis for GTPase activation and its loss in oncogenic Ras mutants JO - Science VL - 277 UR - https://doi.org/10.1126/science.277.5324.333 DO - 10.1126/science.277.5324.333 ID - Scheffzek1997 ER - TY - JOUR AU - Scheffzek, K. AU - Lautwein, A. AU - Kabsch, W. AU - Ahmadian, M. R. AU - Wittinghofer, A. PY - 1996 DA - 1996// TI - Crystal structure of the GTPase-activating domain of human p120GAP and implications for the interaction with Ras JO - Nature VL - 384 UR - https://doi.org/10.1038/384591a0 DO - 10.1038/384591a0 ID - Scheffzek1996 ER - TY - JOUR AU - Downward, J. PY - 2003 DA - 2003// TI - Targeting RAS signalling pathways in cancer therapy JO - Nat Rev Cancer VL - 3 UR - https://doi.org/10.1038/nrc969 DO - 10.1038/nrc969 ID - Downward2003 ER - TY - JOUR AU - Cox, A. D. AU - Fesik, S. W. AU - Kimmelman, A. C. AU - Luo, J. AU - Der, C. J. PY - 2014 DA - 2014// TI - Drugging the undruggable RAS: mission possible? JO - Nat Rev Drug Discov VL - 13 UR - https://doi.org/10.1038/nrd4389 DO - 10.1038/nrd4389 ID - Cox2014 ER - TY - JOUR AU - Dogan, S. AU - Shen, R. AU - Ang, D. C. AU - Johnson, M. L. AU - D’Angelo, S. P. AU - Paik, P. K. PY - 2012 DA - 2012// TI - Molecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancers JO - Clin Cancer Res VL - 18 UR - https://doi.org/10.1158/1078-0432.CCR-11-3265 DO - 10.1158/1078-0432.CCR-11-3265 ID - Dogan2012 ER - TY - JOUR AU - Canon, J. AU - Rex, K. AU - Saiki, A. Y. AU - Mohr, C. AU - Cooke, K. AU - Bagal, D. PY - 2019 DA - 2019// TI - The clinical KRAS (G12C) inhibitor AMG 510 drives anti-tumour immunity JO - Nature VL - 575 UR - https://doi.org/10.1038/s41586-019-1694-1 DO - 10.1038/s41586-019-1694-1 ID - Canon2019 ER - TY - JOUR AU - Ryan, M. B. AU - Fece de la Cruz, F. PY - 2020 DA - 2020// TI - Vertical pathway inhibition overcomes adaptive feedback resistance to KRAS(G12C) inhibition JO - Clin Cancer Res VL - 26 UR - https://doi.org/10.1158/1078-0432.CCR-19-3523 DO - 10.1158/1078-0432.CCR-19-3523 ID - Ryan2020 ER - TY - JOUR AU - Janes, M. R. AU - Zhang, J. AU - Li, L. S. AU - Hansen, R. AU - Peters, U. AU - Guo, X. PY - 2018 DA - 2018// TI - Targeting KRAS mutant cancers with a covalent G12C-specific inhibitor JO - Cell VL - 172 UR - https://doi.org/10.1016/j.cell.2018.01.006 DO - 10.1016/j.cell.2018.01.006 ID - Janes2018 ER - TY - JOUR AU - Dong, Z. Y. AU - Zhong, W. Z. AU - Zhang, X. C. AU - Su, J. AU - Xie, Z. AU - Liu, S. Y. PY - 2017 DA - 2017// TI - Potential predictive value of TP53 and KRAS mutation status for response to PD-1 blockade immunotherapy in lung adenocarcinoma JO - Clin Cancer Res VL - 23 UR - https://doi.org/10.1158/1078-0432.CCR-16-2554 DO - 10.1158/1078-0432.CCR-16-2554 ID - Dong2017 ER - TY - JOUR AU - Liu, C. AU - Zheng, S. AU - Jin, R. AU - Wang, X. AU - Wang, F. AU - Zang, R. PY - 2020 DA - 2020// TI - The superior efficacy of anti-PD-1/PD-L1 immunotherapy in KRAS-mutant non-small cell lung cancer that correlates with an inflammatory phenotype and increased immunogenicity JO - Cancer Lett VL - 470 UR - https://doi.org/10.1016/j.canlet.2019.10.027 DO - 10.1016/j.canlet.2019.10.027 ID - Liu2020 ER - TY - JOUR AU - Falk, A. T. AU - Yazbeck, N. AU - Guibert, N. AU - Chamorey, E. AU - Paquet, A. AU - Ribeyre, L. PY - 2018 DA - 2018// TI - Effect of mutant variants of the KRAS gene on PD-L1 expression and on the immune microenvironment and association with clinical outcome in lung adenocarcinoma patients JO - Lung Cancer. VL - 121 UR - https://doi.org/10.1016/j.lungcan.2018.05.009 DO - 10.1016/j.lungcan.2018.05.009 ID - Falk2018 ER - TY - JOUR AU - Skoulidis, F. AU - Goldberg, M. E. PY - 2018 DA - 2018// TI - STK11/LKB1 mutations and PD-1 inhibitor resistance in KRAS-mutant lung adenocarcinoma JO - Cancer Discov VL - 8 UR - https://doi.org/10.1158/2159-8290.CD-18-0099 DO - 10.1158/2159-8290.CD-18-0099 ID - Skoulidis2018 ER - TY - JOUR AU - Hansen, C. G. AU - Bright, N. A. AU - Howard, G. AU - Nichols, B. J. PY - 2009 DA - 2009// TI - SDPR induces membrane curvature and functions in the formation of caveolae JO - Nat Cell Biol VL - 11 UR - https://doi.org/10.1038/ncb1887 DO - 10.1038/ncb1887 ID - Hansen2009 ER - TY - JOUR AU - Wang, Y. AU - Song, Z. AU - Leng, P. AU - Liu, Y. PY - 2019 DA - 2019// TI - A systematic analysis reveals gene expression alteration of serum deprivation response (SDPR) gene is significantly associated with the survival of patients with cancer JO - Oncol Rep VL - 42 ID - Wang2019 ER - TY - JOUR AU - Luo, Y. AU - Wu, J. AU - Wu, Q. AU - Li, X. AU - Wu, J. AU - Zhang, J. PY - 2019 DA - 2019// TI - miR-577 regulates TGF-beta induced cancer progression through a SDPR-modulated positive-feedback loop with ERK-NF-kappaB in gastric cancer JO - Mol Ther VL - 27 UR - https://doi.org/10.1016/j.ymthe.2019.02.002 DO - 10.1016/j.ymthe.2019.02.002 ID - Luo2019 ER - TY - JOUR AU - Jing, W. AU - Luo, P. AU - Zhu, M. AU - Ai, Q. AU - Chai, H. AU - Tu, J. PY - 2016 DA - 2016// TI - Prognostic and diagnostic significance of SDPR-Cavin-2 in hepatocellular carcinoma JO - Cell Physiol Biochem VL - 39 UR - https://doi.org/10.1159/000447803 DO - 10.1159/000447803 ID - Jing2016 ER - TY - JOUR AU - Wang, Q. X. AU - Chen, E. D. AU - Cai, Y. F. AU - Zhou, Y. L. AU - Dong, S. Y. AU - Zhang, X. H. PY - 2019 DA - 2019// TI - Serum deprivation response functions as a tumor suppressor gene in papillary thyroid cancer JO - Clin Genet VL - 96 UR - https://doi.org/10.1111/cge.13609 DO - 10.1111/cge.13609 ID - Wang2019 ER - TY - JOUR AU - Wang, R. AU - Peng, S. AU - Zhang, X. AU - Wu, Z. AU - Duan, H. AU - Yuan, Y. PY - 2019 DA - 2019// TI - Inhibition of NF-κB improves sensitivity to irradiation and EGFR-TKIs and decreases irradiation-induced lung toxicity JO - Int J Cancer VL - 144 UR - https://doi.org/10.1002/ijc.31907 DO - 10.1002/ijc.31907 ID - Wang2019 ER - TY - JOUR AU - Liu, T. AU - Sun, Q. AU - Li, Q. AU - Yang, H. AU - Zhang, Y. AU - Wang, R. PY - 2015 DA - 2015// TI - Dual PI3K/mTOR inhibitors, GSK2126458 and PKI-587, suppress tumor progression and increase radiosensitivity in nasopharyngeal carcinoma JO - Mol Cancer Ther VL - 14 UR - https://doi.org/10.1158/1535-7163.MCT-14-0548 DO - 10.1158/1535-7163.MCT-14-0548 ID - Liu2015 ER - TY - JOUR AU - DuPage, M. AU - Dooley, A. L. AU - Jacks, T. PY - 2009 DA - 2009// TI - Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase JO - Nat Protoc VL - 4 UR - https://doi.org/10.1038/nprot.2009.95 DO - 10.1038/nprot.2009.95 ID - DuPage2009 ER - TY - JOUR AU - Yano, S. AU - Wang, W. AU - Li, Q. AU - Matsumoto, K. AU - Sakurama, H. AU - Nakamura, T. PY - 2008 DA - 2008// TI - Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations JO - Cancer Res VL - 68 UR - https://doi.org/10.1158/0008-5472.CAN-08-1643 DO - 10.1158/0008-5472.CAN-08-1643 ID - Yano2008 ER - TY - JOUR AU - Peng, S. AU - Wang, R. AU - Zhang, X. AU - Ma, Y. AU - Zhong, L. AU - Li, K. PY - 2019 DA - 2019// TI - EGFR-TKI resistance promotes immune escape in lung cancer via increased PD-L1 expression JO - Mol Cancer. VL - 18 UR - https://doi.org/10.1186/s12943-019-1073-4 DO - 10.1186/s12943-019-1073-4 ID - Peng2019 ER - TY - JOUR AU - Gupta, R. AU - Toufaily, C. AU - Annabi, B. PY - 2014 DA - 2014// TI - Caveolin and cavin family members: dual roles in cancer JO - Biochimie VL - 107 UR - https://doi.org/10.1016/j.biochi.2014.09.010 DO - 10.1016/j.biochi.2014.09.010 ID - Gupta2014 ER - TY - JOUR AU - Ozturk, S. AU - Papageorgis, P. AU - Wong, C. K. AU - Lambert, A. W. AU - Abdolmaleky, H. M. AU - Thiagalingam, A. PY - 2016 DA - 2016// TI - SDPR functions as a metastasis suppressor in breast cancer by promoting apoptosis JO - Proc Natl Acad Sci USA VL - 113 UR - https://doi.org/10.1073/pnas.1514663113 DO - 10.1073/pnas.1514663113 ID - Ozturk2016 ER - TY - JOUR AU - Yu, H. A. AU - Sima, C. S. AU - Shen, R. AU - Kass, S. AU - Gainor, J. AU - Shaw, A. PY - 2015 DA - 2015// TI - Prognostic impact of KRAS mutation subtypes in 677 patients with metastatic lung adenocarcinomas JO - J Thorac Oncol. VL - 10 UR - https://doi.org/10.1097/JTO.0000000000000432 DO - 10.1097/JTO.0000000000000432 ID - Yu2015 ER - TY - JOUR AU - Ihle, N. T. AU - Byers, L. A. AU - Kim, E. S. AU - Saintigny, P. AU - Lee, J. J. AU - Blumenschein, G. R. PY - 2012 DA - 2012// TI - Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome JO - J Natl Cancer Inst VL - 104 UR - https://doi.org/10.1093/jnci/djr523 DO - 10.1093/jnci/djr523 ID - Ihle2012 ER - TY - JOUR AU - Shepherd, F. A. AU - Domerg, C. AU - Hainaut, P. AU - Janne, P. A. AU - Pignon, J. P. AU - Graziano, S. PY - 2013 DA - 2013// TI - Pooled analysis of the prognostic and predictive effects of KRAS mutation status and KRAS mutation subtype in early-stage resected non-small-cell lung cancer in four trials of adjuvant chemotherapy JO - J Clin Oncol VL - 31 UR - https://doi.org/10.1200/JCO.2012.48.1390 DO - 10.1200/JCO.2012.48.1390 ID - Shepherd2013 ER - TY - JOUR AU - Skoulidis, F. AU - Byers, L. A. AU - Diao, L. AU - Papadimitrakopoulou, V. A. AU - Tong, P. AU - Izzo, J. PY - 2015 DA - 2015// TI - Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities JO - Cancer Discov VL - 5 UR - https://doi.org/10.1158/2159-8290.CD-14-1236 DO - 10.1158/2159-8290.CD-14-1236 ID - Skoulidis2015 ER - TY - JOUR AU - Arbour, K. C. AU - Jordan, E. AU - Kim, H. R. AU - Dienstag, J. AU - Yu, H. A. AU - Sanchez-Vega, F. PY - 2018 DA - 2018// TI - Effects of co-occurring genomic alterations on outcomes in patients with KRAS-mutant non-small cell lung cancer JO - Clin Cancer Res VL - 24 UR - https://doi.org/10.1158/1078-0432.CCR-17-1841 DO - 10.1158/1078-0432.CCR-17-1841 ID - Arbour2018 ER - TY - JOUR AU - Schabath, M. B. AU - Welsh, E. A. AU - Fulp, W. J. AU - Chen, L. AU - Teer, J. K. AU - Thompson, Z. J. PY - 2016 DA - 2016// TI - Differential association of STK11 and TP53 with KRAS mutation-associated gene expression, proliferation and immune surveillance in lung adenocarcinoma JO - Oncogene VL - 35 UR - https://doi.org/10.1038/onc.2015.375 DO - 10.1038/onc.2015.375 ID - Schabath2016 ER -